NTLA
NTLA
US45826J1051
Intellia Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 67.671.000 57.877.000
16.9%
Cost of Revenue -- --
--
Gross Profit -- --
--
508.661.000 592.140.000
14.1%
Operating Income -440.990.000 -534.263.000
17.5%
Pretax Income -412.694.000 -519.021.000
20.5%
Net Income Common Stockholders -412.694.000 -519.021.000
20.5%
-- --
--
-- --
--
ende